Efficacy and safety of “unboosting” atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF

References

• Sension M, Andrade Neto JL, Grinsztejn B, et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immun Defic Syndr. 2009;51:153–162.10.1097/QAI.0b013e3181a5701c
   PubMed Web of Science ®Google Scholar
• Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65:1878–1888.10.1093/jac/dkq231
   PubMed Web of Science ®Google Scholar
• Ghosn J, Carosi G, Moreno S, et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther. 2010;15:993–1002.10.3851/IMP1666
   PubMed Web of Science ®Google Scholar
• Squires KE, Young B, DeJesus E, et al. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2012;13:233–244.10.1310/hct1305-233
   PubMed Web of Science ®Google Scholar
• Wohl DA, Bhatti L, Small CB, et al. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine  +  atazanavir. HIV Med. 2016;17:106–117.10.1111/hiv.2016.17.issue-2
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Morello J, Barreiro P, et al. Switch from Ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Human Retroviruses. 2008;24:821–825.10.1089/aid.2007.0276
   PubMed Web of Science ®Google Scholar
• Bonora S, Rusconi S, Calcagno A, et al. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). J Antimicrob Chemother. 2015;70:3096–3099.10.1093/jac/dkv208
   PubMed Web of Science ®Google Scholar
• Taburet A-M, Piketty C, Chazallon C, et al. Interactions between Atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091–2096.10.1128/AAC.48.6.2091-2096.2004
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Page L-30, Table 19c. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed August 25, 2016.
   Google Scholar
• Pavie J, Porcher R, Torti C, et al. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1 infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother. 2011;66:2372–2378.10.1093/jac/dkr316
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–1678.10.1097/QAD.0b013e328339fe53
   PubMed Web of Science ®Google Scholar
• Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207:1359–1369.10.1093/infdis/jit043
   PubMed Web of Science ®Google Scholar
• Hull M, Moore D, Harris M, et al. A lamivudine (3TC)-based backbone in conjunction with a boosted protease inhibitor (PI) is sufficient to achieve virologic suppression in the presence of M184 V mutations. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12–15, 2009. San Francisco, CA. Abstract H-916.
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470.10.7326/0003-4819-130-6-199903160-00002
   Google Scholar
• Dobiás̆ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apob-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001;34:583–588.10.1016/S0009-9120(01)00263-6
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Çiçek G, Ayhan E, Doğan Y. Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: Population-based cohort study. Clin Biochem. 2010;43:1381–1386.10.1016/j.clinbiochem.2010.08.027
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serna A, Swenson LC, Watson B, et al. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. Clin Microbiol Infection 2016;22:1004.e9–1004.e16.
   Google Scholar
• Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr. 2009;51:3–6.10.1097/QAI.0b013e31819e721b
   PubMed Web of Science ®Google Scholar
• Gonzalez de Requena D, Bonora S, Cavechia I, et al. Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: definition of therapeutic range. 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28–30 2005, Quebec City, Canada. Abstract 60.
   Google Scholar
• Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir ctrough is associated with efficacy and safety: definition of therapeutic range. 12th Conference on Retroviruses and Opportunistic Infections; February 22–25 2005, Boston, MA. Abstract 645.
   Google Scholar
• Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C → T polymorphism at the Multidrug Resistance Gene 1. Clin Infect Dis. 2006;42:291–295.10.1086/499056
   PubMed Web of Science ®Google Scholar
• Moltó J, Santos J, Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit. 2007;29:648–651.10.1097/FTD.0b013e31815704c1
   PubMed Web of Science ®Google Scholar
• Cleijsen RMM, van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007;60:897–900.10.1093/jac/dkm298
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0. [November 2014]. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_GRADING_Table_v2_NOV2014.pdf Accessed September 14, 2016.
   Google Scholar
• Fournier C, Higgins N, Thomas R, et al. Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir. Ther Drug Monit. 2013;35:264–269.10.1097/FTD.0b013e3182834057
   PubMed Web of Science ®Google Scholar
• Calcagno A, Bonora S, Tettoni MC, et al. Tenofovir coadministration is not associated with lower unboosted atazanavir exposure in the clinical setting. J Acquir Immune Defic Syndr. 2009;52:431–432.
   PubMed Web of Science ®Google Scholar
• Tsai M-S, Chang S-Y, Lin S-W, et al Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1 infected patients who have achieved virological suppression: a therapeutic drug monitoring and pharmacogenetic study. J Microbiol, Immunol Infection. 2016. http://dx.doi.org/10.1016/jmii.2015.12.012
   Google Scholar
• Gross R, Yip B, Lo Re V, III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV‐1 suppression. J Infect Dis. 2006;194:1108–1114.10.1086/jid.2006.194.issue-8
   PubMed Web of Science ®Google Scholar
• Park WB, Choe PG, Song KH, et al. Genetic factors influencing severe atazanavir‐associated hyperbilirubinemia in a population with low UDP‐glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis. 2010;51:101–106.10.1086/652975
   PubMed Web of Science ®Google Scholar
• Izzedine H, Mʼrad MB, Bardier A, Daudon M, Salmon D. Atazanavir crystal nephropathy. AIDS. 2007;21:2357–2358.10.1097/QAD.0b013e3282f17503
   PubMed Web of Science ®Google Scholar
• Hara M, Suganuma A, Yanagisawa N, Imamura A, Hishima T, Ando M. Atazanavir nephrotoxicity. Clin Kidney J. 2015;8:137–142.10.1093/ckj/sfv015
   PubMed Web of Science ®Google Scholar
• Marinescu CI, Leyes M, Ribas MA, et al. Relationship between serum levels of atazanavir and renal toxicity or lithiasis. AIDS Research and Treatment. 2015;2015:1–7.
   Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Labarga P, D’Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24:1064–1066.10.1097/QAD.0b013e32833202e2
   PubMed Web of Science ®Google Scholar
• Poizot-Martin I, Solas C, Allemand J, et al. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2013;62:375–380.10.1097/QAI.0b013e31827ce4ee
   PubMed Web of Science ®Google Scholar
• Ezinga M, Wetzels JF, Bosch ME, van der Ven AJ, Burger DM. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration. Antivir Ther. 2014;19(8):765–771. doi:10.3851/IMP2761.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Gonzalez de Requena D, Simiele M, et al. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob Agents Chemother. 2013;57:1840–1843.10.1128/AAC.02434-12
   PubMed Web of Science ®Google Scholar
• Young B, Squires KE, Ross LL, et al. Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naïve HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses. 2013;29:350–358.
   PubMed Web of Science ®Google Scholar
• Lawson EB, Martin H, McCallister S, et al. GS-US-292-0112 Study Team. Drug interactions between tenofovir alafenamide and HIV antiretroviral agents. In: Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 5–9, 2014; Washington, DC. Abstract H-1012.
   Google Scholar